Sunshine Lake Pharma Co., Ltd.

This study was designed to test the safety and effectiveness of ningetinib (CT053PTSA) in people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called MET exon 14 skipping. It planned to enroll adults aged 18-75 with stage IIIB-IV cancer. Howe…

This study tests a new tablet called HEC585 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 270 adults aged 40-80 will take either HEC585, a placebo, or an existing drug (pirfenidone) for 24 weeks. The main …